QIBA Process Committee Meeting

Tuesday, September 6, 2022, at 2 pm (CT)

Meeting Summary

Attendees:		**RSNA Staff:**
Kevin O'Donnell, MASc (Chair)	Caroline Chung, MD	Joe Koudelik
Michael Boss, PhD (Vice Chair)	Dan Sullivan, MD	Susan Stanfa

Next Steps / Action Items:

Review of Estimates of Precision Guidance Text

- Document provides guidance on drafting assessment procedures for Profiles at Stage 3 (Clinically Feasible) and Stage 4 (Claim Confirmed) to test the:
  - Conformance of an actor, and
  - Composite performance of a site (e.g., to compare against the performance described in the Claim itself)

- The Process Cmte agreed on the following minimum Stage 4 Trial requirements, which are intended to be applicable across modalities:
  - Two or more independent clinical sites, though additional sites may be encouraged
  - The same clinical sites as used in stage 3 (to assess practicality) may be used in stage 4 (to assess performance)
  - Two or more scanner vendors between the two sites as a baseline requirement, but BCs to decide whether this is sufficient based on their specific situations, e.g., QIB, diversity of models across vendors, etc.
  - Three or more machines (ideally different models)

- Institutional quality improvement projects suggested as a potential route to recruit Stage 4 sites; this research route has fewer participation hurdles, e.g., does not require IRB approval, less administrative red tape, etc.
- Discussion to be continued during the next meeting on Sept. 20
- Agendas can be found on the Process Cmte page of the QIBA Wiki

Next Process Committee Meeting: Tuesday, September 20, 2022, at 2 p.m. (CT) **[1st & 3rd Tuesdays]**

Zoom link: https://rsna-org.zoom.us/j/89877175730?pwd=V282c2FPSU1vdDhWejJrSGZYZTVZdz09
Meeting ID: 898 7717 5730
Passcode: Process